Literature DB >> 4060747

Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status.

C Rose, H T Mouridsen, S M Thorpe, J Andersen, M Blichert-Toft, K W Andersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4060747     DOI： 10.1007/BF01655192

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  22 in total

1.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

2.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

3.  Organisation of the Danish adjuvant trials in breast cancer.

Authors:  K W Andersen; H T Mouridsen; T Castberg; K Fischerman; J Andersen; K Hou-Jensen; H Brincker; H Johansen; E Henriksen; M Rørth; N Rossing
Journal:  Dan Med Bull       Date:  1981-08

4.  Hormonal control of growth and progression in tumors of Nb rats and a theory of action.

Authors:  R L Noble
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

5.  Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.

Authors: 
Journal:  Lancet       Date:  1984-06-09       Impact factor: 79.321

6.  Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.

Authors:  O H Pearson; C A Hubay; J S Marshall; N H Gordon; W L McGuire; E G Mansour; R E Hermann; J C Jones; W J Flynn; C Eckert
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

7.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.

Authors:  B Fisher; C Redmond; A Brown; D L Wickerham; N Wolmark; J Allegra; G Escher; M Lippman; E Savlov; J Wittliff
Journal:  J Clin Oncol       Date:  1983-04       Impact factor: 44.544

8.  Oestrogen receptors and prognosis in early breast cancer.

Authors:  T Cooke; D George; R Shields; P Maynard; K Griffiths
Journal:  Lancet       Date:  1979-05-12       Impact factor: 79.321

9.  Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute.

Authors:  G Ribeiro; M K Palmer
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-12

10.  Oestrogen-receptor status and sites of metastasis in breast cancer.

Authors:  F C Campbell; R W Blamey; C W Elston; R I Nicholson; K Griffiths; J L Haybittle
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640
View more
  4 in total

Review 1.  Adjuvant systemic therapy: state of the art, 1989.

Authors:  I C Henderson
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

2.  A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer.

Authors:  M Stierer; H Rosen; R Weber; H Hanak; L Auerbach; J Spona; H Tüchler
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 3.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

4.  A pilot study of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Kai Siang Chan; Bernard Chi Shern Ho; Vishal G Shelat
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.